Aug 15, 2018 · Onpattro FDA Approval History Last updated by Judith Stewart, BPharm on Aug 15, 2018. FDA Approved: Yes (First approved August 10, 2018) Brand name: Onpattro …

Aug 10, 2018 · ONPATTRO was approved by the U.S. Food and Drug Administration (FDA) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis …

Patisiran was granted orphan drug status, fast track designation, priority review and breakthrough therapy designation due to its novel mechanism and the rarity of the condition it treats. [14][15] …

3 days ago · The FDA has approved the first ever RNA interference drug – Alnylam’s Onpattro (patisiran) for the nerve damage caused by the rare disease hereditary transthyretin-mediated …

Please refer to your New Drug Application (NDA) dated December 11, 2017, received December 11, 2017, and your amendments, submitted under section 505(b) of the Federal Food, Drug, …

The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin …

Dec 4, 2025 · Onpattro was FDA approved on August 10, 2018. Learn about this landmark approval for the first RNAi therapy to treat hATTR amyloidosis.

On August 10, 2018, the US FDA approved Alnylam Pharmaceuticals' first RNA interference -based therapeutic drug Onpattro (Patisiran) for the treatment of peripheral neuropathy caused …

Jan 26, 2023 · Onpattro® (patisiran): Approved in August 2018 for the treatment of polyneuropathy in hATTR amyloidosis. For more information, please visit the Onpattro® …

Oct 9, 2013 · Onpattro was developed by Alnylam Pharmaceuticals and granted approval by the US Food and Drug Administration (FDA) in August 2018 for the treatment of adults with ATTR …